Related Experiment Video
Updated: May 14, 2025

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
Identification of osteoarthritis-associated chondrocyte subpopulations and key gene-regulating drugs based on
Ting Hao1, Zhiwei Pei2, Sile Hu3
1The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, China.
Abstract:
The mechanism by which chondrocytes respond to mechanical stress in joints significantly affects the balance and function of cartilage. This study aims to characterize osteoarthritis-associated chondrocyte subpopulations and key gene targets for regulatory drugs. To begin, single-cell and transcriptome datasets were obtained from the Gene Expression Omnibus (GEO) database. Cell communication and pseudo-temporal analysis, as well as High-dimensional Weighted Gene Co-expression Network Analysis (hdWGCNA), were conducted on the single-cell data to identify key chondrocyte subtypes and module genes. Subsequently, Consensus Cluster Plus analysis was utilized to identify distinct disease subgroups within the osteoarthritis (OA) training dataset based on the key module genes. Furthermore, differential gene expression analysis and GO/KEGG pathway enrichment analysis were performed on the identified subgroups. To screen for hub genes associated with OA, a combination of 10 machine learning algorithms and 113 algorithm compositions was integrated. Additionally, the immune and pathway scores of the training dataset samples were evaluated using the ESTIMATE, MCP-counter, and ssGSEA algorithms to establish the relationship between the hub genes and immune and pathways. Following this, a network depicting the interaction between the hub genes and transcription factors was constructed based on the Network Analyst database. Moreover, the hub genes were subjected to drug prediction and molecular docking using the RNAactDrug database and AutoDockTools. Finally, real-time fluorescence quantitative PCR (RT-qPCR) was employed to detect the expression of hub genes in the plasma samples collected from osteoarthritis patients and healthy adults. In the OA sample, there is a significant increase in the proportion of prehypertrophic chondrocytes (preHTC), particularly in subgroups 6, 7, and 9. We defined these subgroups as OA_PreHTC subgroups. The OA_PreHTC subgroup exhibits a higher communication intensity with proliferative-related pathways such as ANGPTL and TGF-β. Furthermore, two OA disease subgroups were identified in the training set samples. This led to the identification of 411 differentially expressed genes (DEGs) related to osteoarthritis, 2485 DEGs among subgroups, as well as 238 intersecting genes and 5 hub genes (MMP13, FAM26F, CHI3L1, TAC1, and CKS2). RT-qPCR results indicate significant differences in the expression levels of five hub genes and their related TFs in the clinical blood samples of OA patients compared to the healthy control group (NC). Moreover, these five hub genes are positively associated with inflammatory pathways such as TNF-α, JAK-STAT3, and inflammatory response, while being negatively associated with proliferation pathways like WNT and KRAS. Additionally, the five hub genes are positively associated with neutrophils, activated CD4 T cell, gamma delta T cell, and regulatory T cell, while being negatively associated with CD56dim natural killer cell and Type 17T helper cell. Molecular docking results reveal that CAY10603, Tenulin, T0901317, and Nonactin exhibit high binding activity to CHI3L1, suggesting their potential as therapeutic drugs for OA. The OA_PreHTC subgroups plays a crucial role in the occurrence and development of osteoarthritis (OA). Five hub genes may exert their effects on OA through interactions with PreHTC cells, other chondrocytes, and immune cells, playing a role in inhibiting cell proliferation and stimulating inflammation, thus having high diagnostic value for OA. Additionally, CAY10603, Tenulin, T0901317, and Nonactin have potential therapeutic effects for OA patients.
Insights
Osteoarthritis involves increased prehypertrophic chondrocytes (preHTC) and five key genes (MMP13, FAM26F, CHI3L1, TAC1, CKS2) linked to inflammation and immune response. Potential drugs targeting CHI3L1 show promise for osteoarthritis treatment.
Area of Science:
- Biomedical research
- Molecular biology
- Genomics
Background:
- Chondrocyte response to mechanical stress is crucial for cartilage homeostasis.
- Osteoarthritis (OA) involves complex cellular and molecular changes in chondrocytes.
- Identifying specific chondrocyte subpopulations and molecular targets is key for OA treatment.
Purpose of the Study:
- To characterize osteoarthritis-associated chondrocyte subpopulations.
- To identify key gene targets for potential regulatory drugs in OA.
- To explore the role of identified genes in OA pathogenesis and immune response.
Main Methods:
- Analysis of single-cell and transcriptome data from the GEO database.
- Application of cell communication, pseudo-temporal, and hdWGCNA analyses.
- Integration of machine learning algorithms for hub gene identification and drug prediction.
Main Results:
- Identification of OA-associated prehypertrophic chondrocyte (preHTC) subgroups with increased proliferative pathway communication.
- Discovery of five hub genes (MMP13, FAM26F, CHI3L1, TAC1, CKS2) differentially expressed in OA patients.
- Hub genes show associations with inflammatory pathways and specific immune cells; potential OA drugs identified via molecular docking.
Conclusions:
- OA_PreHTC subgroups are critical in OA development, interacting with chondrocytes and immune cells.
- The five identified hub genes play roles in inhibiting proliferation and stimulating inflammation in OA.
- Hub genes possess diagnostic value for OA, and specific compounds show therapeutic potential.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Genomics

